This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Q3 Results Begin: Can We Avoid an Earnings Recession?
by Mark Vickery
Results from JPM, JNJ help paint the picture whether Q3 will bear out better than expected.
Here's Why You Should Hold on to CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) raises 2019 revenue and earnings per share guidance.
J&J (JNJ) Beats Q3 Earnings & Sales, Shares Rise
by Zacks Equity Research
J&J (JNJ) beats estimates for earnings and sales in the third quarter of 2019 and raises 2019 guidance.
JNJ, JP Morgan and UnitedHealth all Beat, Goldman Sachs Misses
by David Borun
A strong start to earnings season sends all the major averages up more than 1%
Johnson & Johnson's (JNJ) Legal Problems Continue to Worry Investors
by Christopher Vargas
Johnson & Johnson (JNJ) is set to report their third quarter results as pending lawsuits loom over the company.
Jumping Over a Low Earnings Bar: Global Week Ahead
by John Blank
We will surely know what the final Q3 earnings growth pace turns out to be when all 500 results are in. But we know this in advance: they will be better than these expectations, and likely close to the flat line that we saw in the first half of the year.
Major Banks To Flood Wall Street with Earnings Data
by Zacks Equity Research
Major Banks To Flood Wall Street with Earnings Data
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
Bank Holiday Ahead of Q3 Earnings, Trade Negotiations
by Mark Vickery
We may expect lower trading volume overall today, largely due to the heavy reportage of Q3 earnings beginning promptly tomorrow morning.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Will Q3 Earnings Drive Dow ETF Higher?
by Sweta Killa
With most blue-chip companies earnings scheduled over the coming weeks and sentiments being mixed, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from a surge in any of the 30 stocks.
Geron Starts Enrollment in Phase III MDS Study on Imetelstat
by Zacks Equity Research
Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.
What to Expect from Q3 Earnings Season with Big Banks Set to Report?
by Sheraz Mian
For Q3 as a whole, total earnings for the index are expected to decline -5% from the same period last year on +4.2% higher revenues, with 11 of the 16 Zacks sectors expected to have lower earnings compared to the year-earlier period...
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector
by Zacks Equity Research
J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Company News For Oct 10, 2019
by Zacks Equity Research
Companies in the news are: JNJ, X, TGT, OCGN
J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case
by Zacks Equity Research
Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.
Johnson & Johnson (JNJ) Stock Moves -0.99%: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $131.84, moving -0.99% from the previous trading session.
Earnings Preview: Johnson & Johnson (JNJ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
by Kinjel Shah
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
by Zacks Equity Research
J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.
J&J Settles Ahead of Multi-District Opioid Trial, Stock Up
by Zacks Equity Research
J&J (JNJ) reaches settlement agreement with Cuyahoga and Summit counties in Ohio concerning the lawsuits pending in MDL.
Company News For Oct 3, 2019
by Zacks Equity Research
Companies in the news are: SVRA, LEN, F, JNJ
Novartis Reports Additional Data on Spondylitis Drug Cosentyx
by Zacks Equity Research
Novartis (NVS) announces additional positive data from the phase III PREVENT study on spondylitis drug, Cosentyx.